Skip to main content

Table 3 Validation of the serum cytokine array experiment in the initial screening cohort

From: An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes

Cytokine

Method

PSP/CBS

MSA

PD

Controls

p-value

ICAM-1

Array

0.98 ± 0.25

0.47 ± 0.09

0.62 ± 0.15

1.00 ± 0.28

<0.05a

(ICAM1)

FCM

1.25 ± 0.85

0.75 ± 0.29

0.86 ± 0.43

1.00 ± 0.73

nsb

IL-2 Ra

Array

2.14 ± 0.47

1.87 ± 0.10

1.24 ± 0.06

1.00 ± 0.14

<0.05a

(IL2RA)

ELISA

1.44 ± 0.76

1.24 ± 0.61

1.15 ± 0.55

1.00 ± 0.29

nsb

Leptin

Array

1.93 ± 0.11

1.13 ± 0.23

1.91 ± 0.46

1.00 ± 0.11

<0.05a

(LEP)

FCM

2.95 ± 4.89

1.42 ± 1.15

1.86 ± 1.88

1.00 ± 0.89

nsb

MCP-4

Array

7.18 ± 0.85

2.16 ± 1.39

1.71 ± 0.80

1.00 ± 0.76

<0.05a

(CCL13)

ELISA

1.15 ± 0.32

0.91 ± 0.37

1.02 ± 0.32

1.00 ± 0.42

nsb

PDGF-BB

Array

1.87 ± 0.50

1.34 ± 0.18

1.34 ± 0.22

1.00 ± 0.44

<0.05a

(PDGFB)

FCM

1.42 ± 0.30

1.32 ± 0.39

1.11 ± 0.28

1.00 ± 0.33

<0.05b

Prolactin

Array

4.17 ± 1.74

1.03 ± 0.15

0.99 ± 0.08

1.00 ± 0.19

<0.05a

(PRL)

ELISA

3.06 ± 4.15

1.39 ± 1.34

0.71 ± 1.12

1.00 ± 0.50

<0.05b

RANTES

Array

1.46 ± 0.29

1.32 ± 0.11

1.20 ± 0.25

1.00 ± 0.20

<0.05a

(CCL5)

ELISA

1.13 ± 0.59

0.83 ±0.49

0.94 ± 0.32

1.00 ± 0.51

nsb

  1. Cytokine microarray data were validated by ELISA (MCP-4, prolactin, RANTES and IL-2RA) or by Flow-Cytomix assays (ICAM-1, Leptin and PDGF-BB) in individual samples. All data are shown as means with standard deviations of the ratio to the mean of the control group. Array = Raybiotech cytokine microarray, FCM = Flow-Cytomix, ELISA = enzyme-linked immunosorbent assay, ns = statistically non significant.
  2. P-value: groups were compared using a SAM analysis and b Kruskal-Wallis test.